Acute Pharmacological Effects and Oral Fluid Concentrations of the Synthetic Cannabinoids JWH-122 and JWH-210 in Humans After Self-Administration : An Observational Study
Martínez, Lucia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
La Maida, Nunzia (University Politecnica delle Marche (Ancona, Itàlia))
Papaseit, Esther (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Pérez-Mañá, Clara (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Poyatos, Lourdes (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Pellegrini, Manuela (Istituto Superiore di Sanità)
Pichini, Simona (Istituto Superiore di Sanità)
Ventura, Mireia (Associació Benestar i Desenvolupament (Barcelona))
Galindo, Liliana (University of Cambridge/Cambridgeshire and Peterborough NHS Foundation Trust)
Busardo, Francesco Paolo (Università Politecnica delle Marche (Ancora, Itàlia))
Farré Albaladejo, Magí (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)

Data:	2021
Resum:	Synthetic cannabinoids (SCs) are a group of new psychoactive drugs used recreationally with potential health risks. They are monitored by the EU Early Warning System since 2010 due to severe adverse effects on consumers. JWH-122 and JWH-210 are naphthoylindole SCs and potent cannabinoid receptor CB1 and CB2 agonists. Information about the effects of SCs usually is available from intoxication cases and surveys, and few studies on humans after controlled administration or observational/naturalistic studies using standardized measures of cardiovascular and subjective effects are available. The aim of this study was to evaluate the acute pharmacological effects of JWH-122 and JWH-210 recreational consumption in a 4 h observational study and assess their disposition in oral fluid (OF). Sixteen volunteers self-administered 1 mg dose of JWH-122 (n = 8) or 2. 25 mg mean dose of JWH-210 (range 2-3 mg, n = 8) by inhalation (smoking). Physiological parameters including blood pressure (systolic and diastolic), heart rate (HR), and cutaneous temperature were measured. A set of visual analog scales, the 49-item short-form version of the Addiction Research Center Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) were used for the evaluation of subjective effects. OF was collected at baseline and at 10, 20, and 40 min and 1, 2, 3, and 4 h after self-administration. Statistically significant increases in systolic blood pressure (SBP), diastolic blood pressure (DBP), and HR were observed after JWH-122 self-administration but not after JWH-210 self-administration. JWH-210 self-administration produced significant changes in subjective drug effects, similar to those induced by THC (intensity, high, good effects, and hunger). The subjective effects following JWH-122 consumption were minimal. The maximal effects were mostly observed 20 min after intake. JWH-122 and JWH 210 OF concentration reached a peak 20 min after administration and could not be detected after 3 h. The results demonstrated a different pattern of effects of these two SCs. Due to the limitations of our observational study, further research with a larger sample and controlled studies are needed to better define the acute pharmacological effect and health risk profile of JWH-122 and JWH-210.
Ajuts:	Ministerio de Economía y Competitividad PI14/00715 Instituto de Salud Carlos III PI17/01962 Instituto de Salud Carlos III PI20/00804 Ministerio de Economía y Competitividad RD16/0017/0003 Ministerio de Economía y Competitividad RD16/0017/0010 Generalitat de Catalunya 2017SGR316 Generalitat de Catalunya 2017SGR530 Instituto de Salud Carlos III FI18/00179
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	JWH-122 ; JWH-210 ; Synthetic cannabinoid receptor agonists (SCRAs) ; Physiological effects ; Subjective effects
Publicat a:	Frontiers in Pharmacology, Vol. 12 (august 2021) , ISSN 1663-9812

DOI: 10.3389/fphar.2021.705643
PMID: 34489699

9 p, 787.9 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats